Title:
Development and Optimization of Novel Chimeric Antigen Receptor NK-cell Therapeutics for B-Cell Malignancy
Agreement Value:
$100,000.00
Agreement Date:
Mar 31, 2020 - Mar 31, 2021
Description:
To assess the functionality of novel NRC-developed chimeric antigen receptors (CARs) targeting leukemia in primary NK cells and assessment of CAR-NK potential for therapeutic development, expanded primary NK cells will be transduced, and their anti-tumor response will be evaluated in vitro and in vivo.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1N 6N5
Reference Number:
172-2019-2020-Q4-947410
Report Type:
Grants and Contributions
Recipient Business Number:
119278877
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 184 days. The total amended value is 50,000 dollars.
Recipient's Operating Name:
University of Ottawa
Recipient's Legal Name:
University of Ottawa
Federal Riding Name:
Ottawa–Vanier
Federal Riding Number:
35078
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.